Discussion  by unknown
General Thoracic Surgery Puri et al
G
T
Sit was often determined that surgical staging would not sig-
nificantly alter the treatment plan. Moreover, modeling al-
ways involves a degree of simplification, and a model
should not be faulted because available data do not meet
the ideal standards of scientific evidence.
The ideal scenario for conducting cost-effectiveness anal-
yses in medicine is when cost and utility data are collected
prospectively in a randomized controlled trial. For the cur-
rent comparison between SBRT and surgical intervention
in the high-risk patient with lung cancer, such a trial is cur-
rently underway (American College of Surgeons Oncology
Group Z4099/RTOG 1021), and a cost-effectiveness analy-
sis is planned. Data collected from this and other, similar
larger population-based studies will further clarify the rela-
tive cost-effectiveness of surgical intervention and SBRT.References
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Dr Alessandro Brunelli (Ancona, Italy). Mr Chairmen, col-
leagues. I have no conflicts of interest to disclose.
Dr Puri, I want to congratulate you and your colleagues from St
Louis for this timely and interesting contribution. As usual, your
group has performed this very accurate analysis in the context of
a nonrandomized observational investigation. SBRT is emerging
as an effective treatment for functionally inoperable NSCLC.
However, you have demonstrated with a decision model that sur-
gical intervention remains cost-effective, even for these high–
risk patients. I have 3 comments and questions, and I will ask
you one at a time.
Although propensity scoring was appropriately applied in an at-
tempt to minimize the selection bias, the 2 groups of patients did
not seem quite well matched. Surgical patients were more fre-
quently male and had higher FEV1 and DLCO values. Also, the
vast majority of surgical patients underwent lobectomy instead
of minor resection. In my opinion SBRT should be best compared
with minor resection instead of lobectomy. Minor resection consti-
tuted only 19% of your surgical series. Have you tried to restrict
the matching analysis only to minor resections? This would prob-
ably improve your matching and probably will influence the out-
come of the decision model.
Dr Puri. Dr Brunelli, that is a very appropriate comment. For
PSM, just to give you a little bit of background, we had about
500 patients in the surgical arm and about 85 patients in the stereo-
tactic radiation arm, which was used as a dataset for abstracting
these 57 patients. At the very outset, we set extremely stringent cri-
teria in terms of comorbidities and lung function tests to match
these patients. We came up with about 28 or 30 patients we could
actually match, therefore about 15 in each arm, which eventually
led us to believe that there was no way that we could keep subse-
quent criteria and come up with a number of patients who could
actually be analyzed.
Therefore we used the caliper matching method; I showed you
a slide in which the caliper radius that was used was 0.005. There-
fore in a caliper matching method, which essentially means at theery c February 2012
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Scenter of the circle, the patients are perfectly matched. Then you
use a radius and draw a circle around that center. All the patients
who fall within that circle are considered well matched by using
the propensity score analysis. Therefore if you increase the radius
of the caliper, a larger number of patients will be well matched by
means of PSM.
When we used extremely stringent radius criteria, we again
came up with about 25 or 30 patients who could be matched.
Therefore we had to gradually make our criteria more lax to
come up with an analyzable number of patients. Thus we do
have, I would say, an unmeasurable bias against the patients under-
going SBRT, but this is the best PSM that we could achieve.
Dr Brunelli. In the construction of the propensity score, you
used the adult comorbidity evaluation score. By the nature of the
patients under analysis and the methodology used to calculate
the overall score, the majority of the patients had an overall score
of 2 or 3, making this parameter less than ideal to discriminate be-
tween high-risk and low-risk patients in this context. Have you
tried to use more individual and more specific parameters, such
as FEV1, DLCO, the presence of coronary artery disease, or body
mass index, along with the ACE score, to improve your propensity
score construction?
Dr Puri. The ACE–27 score is a score that is collected prospec-
tively, and as Dr Brunelli points out, it goes from mild problems
(ie, level I) to moderate (ie, level II) and severe (ie, level III) co-
morbidity, and most of the patients had moderate or severe comor-
bidities that were either level II or level III. Again, whenwe tried to
use the ACE–27 score in addition to using FEV1, the number of
patients we could come up with that could be extremely well
matched was quite small and not analyzable.
Dr Brunelli. Finally, almost 21% of the patients in the surgical
arm turned out to be N-node positive, and 50% of them were sub-
mitted to adjuvant chemotherapy. However, in the decision model
patients undergoing SBRTwere all regarded as having pathologi-
cal stage 1 disease because they had no nodal biopsy. Did some of
these patients undergo chemotherapy in addition to SBRT?We as-
sume that at least an equal proportion of patients undergoing SBRT
would have node-positive disease, at least equal to the surgical pa-
tients. Have you tried to repeat the analysis by adding lymph node
staging and chemotherapy probability nodes in the decision
models also for the SBRT group, assuming the same probability
of the surgical population? Do you have any data from your center
or from the literature of concurrent SBRT and chemotherapy on
which to base this methodological approach?
I thank the Association for the privilege to discuss this excellent
article. Thank you very much.
Dr Puri. Dr Brunelli, with regard to your last point, you are en-
tirely correct in biologically assuming that the incidence of nodal
disease would be expected to be the same in the 57 patients under-
going SBRT as in the surgical patients. None of these patients re-
ceived chemotherapy up front, and therefore they were all treated
with stereotactic radiation. As we accumulated more data on recur-
rences, either nodal, distant, or local, theywere givenmore therapy.
However, we do not have any data for up-front chemotherapy along
with stereotactic radiation in our population, and I do not believe
any such data have been published in the literature.
As far as using the same assumption in a decision model, one
could do so, but one would not have the results of that assumption.The Journal of Thoracic and CaFor example, in our surgical patients we know which patients ac-
tually had nodal disease, and we do have outcomes in those pa-
tients as having a shorter overall and cause-specific survival.
However, in the SBRT population, we do not have that privilege
because we do not have pathological staging, therefore we cannot
really use that assumption within the decision model within the
construct of the 114 patients from our own center.
Thank you.
DrHiran Fernando (Boston, Mass). That was an excellent pre-
sentation. I am glad that you put in the plug for the Z4099 study, in
which I hope many people here will enroll patients.
I have a couple of questions. In your original report of your
SBRT experience, you had a number of patients with no tissue di-
agnosis, and therefore there were clinically suspicious lung can-
cers that were treated. In this model that you created for your
propensity analysis, was pathological confirmation of lung cancer
a requirement, or did you include patients who did not have a tissue
diagnosis?
Dr Puri. There were 5 or 6 patients in this population who did
not have a tissue diagnosis. Of these patients, several had recur-
rence at some point, and thereforewe eventually had a pathological
diagnosis in these patients. However, of the 57 patients, only
a handful did not have tissue diagnosis.
Dr Fernando. Therefore I would suggest that another factor
that should be included is the need for tissue diagnosis and then
model in the pneumothorax rate that you might see with that and
the need for admission to the hospital that you might need for
the pneumothorax rate and perhaps look at it that way.
Also, in your morbidity outcomes you described the radiation
morbidity. Did you have that morbidity taken out to 3, 6, or 9
months, when you might see the effects of radiation, pneumonitis,
and the effect on pulmonary function?
Dr Puri. Correct. This morbidity was calculated over a period
of 9 months from the time of initial radiation. The 1 major morbid-
ity was a significant pneumonia requiring hospitalization. There
were several minor complications, none of which required hospi-
talization, including rib fractures and a small incidence of pleural
effusions. However, none of these were treated as an inpatient and
did not significantly change the cost curve in this particular anal-
ysis; therefore I did not specifically mention those minor
complications.
Dr David Sugarbaker (Boston, Mass). I enjoyed your article
very much, and I think your whole group is to be congratulated.
I just have one question, and it is really always the looming con-
cern, particularly in a retrospective trial: bias. Presumably, each
one of the patients undergoing SBRT were selected for SBRT
based on a variety of different factors, one of which would be
the presence or absence of N2 disease. One of the indicators to
me that some bias might have played a role here, which I think
we just have to account for, is the higher detectable N2 disease;
it was about 20%, as I saw, for the surgically resected group.
Therefore I wonder whether you could comment a little bit on
bias playing into your results, which is obviously something that
we avoid with an intent-to-treat design.
Thank you very much. I enjoyed your article.
Dr Puri. Thank you. Bias, as Dr Sugarbaker points out, is an in-
trinsic part of any retrospective analysis. First, there is a selection
bias both for the surgical and SBRT arms. We carefully read theserdiovascular Surgery c Volume 143, Number 2 435
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Spatients, and as you saw, 85% of them had undergone a lobectomy.
Therefore as a group of surgeons, we had considered those patients
fit enough to undergo a lobectomy. The majority of patients who
were referred for stereotactic radiation had been seen by our group
and had been denied a lobar resection and thus were discussed at
a multidisciplinary conference and referred for stereotactic radia-
tion. A minority of patients had chosen not to have an operation
and thus underwent stereotactic radiation. All patients, with the ex-
ception of a small handful, probably about 3 or 4 patients in this
57–patient population in the SBRT group, had undergone436 The Journal of Thoracic and Cardiovascular Surgcomputed tomographic and positron emission tomographic scan-
ning to rule out, as effectively as possible, nodal disease in these
patients. Because the study patients were from the 2004–2007
era, we have become even more stringent in trying to rule out path-
ological nodal disease in patients being referred for nonoperative
therapies. With the advent of endobronchial ultrasonography and
with the rather routine use of the video mediastinoscopy and the
availability of endoscopic ultrasonography, I would say in the cur-
rent day and age that we have better pathological mediastinal stag-
ing than from the timeframe in which this study was conducted.ery c February 2012
